Effect of Semaglutide and Empagliflozin on Pulmonary Structure and Proteomics in Obese Mice
Yu Yang,Xiaoyu Pan,Shuchun Chen
DOI: https://doi.org/10.2147/dmso.s456336
2024-03-12
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Yu Yang, 1, 2 Xiaoyu Pan, 1, 3 Shuchun Chen 1, 3 1 Department of Internal Medicine, Hebei Medical University, Shijiazhuang, People's Republic of China; 2 Department of Pharmacy, The Second Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China; 3 Department of Endocrinology, Hebei General Hospital, Shijiazhuang, People's Republic of China Correspondence: Shuchun Chen, Department of Endocrinology, Hebei General Hospital, 348 Heping West Road, Shijiazhuang, Hebei, 050051, People's Republic of China, Tel/Fax +86 311 85988406, Email Objective: This study utilized proteomics to investigate changes in protein expression associated with lung health in obese mice exposed to semaglutide and empagliflozin through a high-fat diet. Methods: Twenty-eight male C57BL/6JC mice were randomly assigned to two groups: a control diet group (n = 7) and a high-fat diet group (n = 21). The HFD group was further divided into three groups: HFD group (n = 7), Sema group (n = 7), and Empa group (n = 7). Post-treatment, mice underwent assessments including glucose tolerance, lipids, oxidative stress markers, body weight, lung weight, and structure. Proteomics identified differentially expressed proteins (DEPs) in lung tissue, and bioinformatics analyzed the biological processes and functions of these proteins. Results: Semaglutide and empagliflozin significantly attenuated obesity-induced hyperglycemia, abnormal lipid metabolism, oxidative stress response, and can decrease alveolar wall thickness, enlarge alveolar lumen, and reduce collagen content in lung tissue. Both medications also attenuated lung elastic fibre cracking and disintegration. In the HFD/NCD group, there were 66 DEPs, comprising 30 proteins that were increased and 36 that were decreased. Twenty-three DEPs overlapped between Sema/HFD and Empa/HFD, with 11 up-regulated and 12 down-regulated simultaneously. After analysing DEPs in different groups, four proteins - LYVE1, BRAF, RGCC, and CHMP5 - were all downregulated in the HFD group and upregulated by semaglutide and empagliflozin treatment. Conclusion: This study demonstrates that obesity induced by a high-fat diet causes a reduction in the expression of LYVE1, BRAF, RGCC, and CHMP5 proteins, potentially affecting lung function and structure in mice. Significantly, the administration of semaglutide and empagliflozin elevates the levels of these proteins, potentially offering therapeutic benefits against lung injury caused by obesity. Merging semaglutide with empagliflozin may exert a more pronounced impact. Keywords: semaglutide, empagliflozin, proteomics, obesity, pulmonary structure In recent years, there has been a sharp rise in the prevalence of obesity around the globe. The World Health Organization's most recent figures indicate that the amount of adults worldwide who are overweight or obese is close to 2 billion, and this figure is on the rise. 1 Obesity, characterized by an excessive accumulation of fat in fat cells, is a complex and chronic condition associated with resistance to insulin, elevated blood pressure, and irregular lipid concentrations. 2 Obesity has a direct impact on the mechanical properties of the lung and chest wall by causing fat to accumulate in the mediastinum and abdominal and thoracic cavities. 3 Consequently, the diaphragm is elevated, restricting its downward movement and resulting in heightened pleural pressure and reduced functional residual capacity. 4,5 Obesity can lead to a decrease in lung, chest wall, and respiratory system compliance, potentially contributing to respiratory issues commonly experienced by many obese individuals. 6 The multifactorial influence of obesity on the lung involves mechanical injury and the role of various inflammatory mediators produced by excess adipose tissue and infiltrating immune cells. Obesity-related lung disease exhibits distinct characteristics, affecting both disease severity and treatment effectiveness, compared to other pulmonary pathologies. Notably, obstructive sleep apnea and obesity hypoventilation syndrome are closely associated with obesity. 7,8 Obesity has also been linked to a variety of other respiratory illnesses, such as asthma, COPD, and pulmonary fibrosis. 9–11 In contrast to genomics, proteomics aims to elucidate the entirety of proteins expressed within a cell or organism. 12 The recent advancements in proteomics have become indispensable for diagnosing and understanding metabolic diseases like diabetes and obesity, while also significantly impacting pharmaceutical development. 13–15 Enteroendocrine L-cells in the ileum primarily secrete glu -Abstract Truncated-
endocrinology & metabolism